Every material Form 8-K Aptevo Therapeutics Inc. has filed with the SEC since October 26, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Aptevo Therapeutics reported on November 9, 2026 that it presented new preclinical data from its next-generation multispecific platform at the SITC 2026 Annual Meeting on November 7, 2026. The lab results cover APVO451, APVO452 and APVO711, which the company says showed tumor-cell killing and immune activation under conditions that suppress immune responses. The filing contains no financial results, and the data are early-stage, so the update does not change reported financials.
Presentation made on November 7, 2026 at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting.
APVO451 and APVO452 showed tumor-cell killing and T-cell activation under immunosuppressive conditions in preclinical studies.
APVO711 combined CD40 activation with PD-L1 checkpoint blockade in preclinical findings.
APVO451 and APVO452 are expected to advance into IND-enabling studies in 2027.
Aptevo Therapeutics said successive refinements to the priming-dose regimen for its lead candidate, mipletamig, substantially reduced infusion-related reactions in the ongoing RAINIER study in frontline acute myeloid leukemia. The company said the change supports its preparation for Phase 2 development, which it expects to initiate in 2027, but the filing gives no numerical measure of the reduction and states that the findings do not establish improved efficacy.
Successive priming-dose refinements substantially reduced infusion-related reactions, per the press release; no reduction percentage is disclosed.
Mipletamig data will be presented at the ASH 68th Annual Meeting, December 12-15, 2026, in New Orleans.
Aptevo expects to complete the RAINIER study by year-end 2026 and initiate Phase 2 development in 2027.
Aptevo Therapeutics filed a prospectus supplement under its existing Form S-3 shelf registration covering up to $2,309,834 of common stock to be sold through an at-the-market program with Roth Capital Partners. The company said it had previously sold 303,157 shares for gross proceeds of $11.8 million under the same agreement, so new sales could dilute existing shareholders.
Offering of up to $2,309,834 in common stock under the April 28, 2025 At The Market Offering Agreement with Roth Capital Partners, LLC
Prior sales under the agreement: 303,157 shares for aggregate gross proceeds of $11.8 million
Paul Hastings LLP issued a legal opinion on the shares, filed as Exhibit 5.1
Filing dated October 30, 2026; 8-K signed November 2, 2026
Aptevo reported that ten patients with newly diagnosed acute myeloid leukemia treated with mipletamig plus venetoclax and azacitidine have advanced to allogeneic stem cell transplant. The company said the data is a clinical update from its Phase 1b RAINIER trial and one earlier dose expansion trial, and it does not include any financial results or guidance.
Ten of 47 (21%) evaluable frontline patients treated with mipletamig plus venetoclax and azacitidine proceeded to transplant, including nine from RAINIER and one from the prior dose expansion trial.
The company cited the Phase 3 VIALE-A trial, in which three of 286 patients (0.7%) receiving venetoclax and azacitidine alone later underwent transplant, and noted that cross-trial comparisons have limits.
Aptevo expects to complete RAINIER dose optimization by year-end 2026 and discuss next steps with regulators in the first half of 2027.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Aptevo Therapeutics Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →